OTC
15.22USD
+0.81 (+5.62%)
We have scored 12 news catalysts on Bayer AG (BAYRY) over the past 12 months. The biggest single-day move next to one of them came Feb 18, 2026, when BAYRY closed −7.6%: “Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains?”. Coverage across the window leans positive (average ticker sentiment +0.61). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
59.8B
P/E
—
EPS
—
Beta
0.83
52W range
7.48-15.24
Day range
14.95–15.25
Open
15.05
Prev close
14.41
Volume
320.4K
Avg volume
671.2K
Dividend
0.03
IPO
1996-11-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Bayer AG — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BAYRY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
